glp 1 and seizures LY3437943, a novel triple glucagon, GIP, GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Mapping the effectiveness and risks

For clinicians, the takeaway is not yet a change in practice but a shift in perspective

The extended pharmacokinetic profile allows therapeutic GLP-1 receptor activation throughout the day and night, providing continuous metabolic benefits rather than the transient effects of native GLP-1

General inflammatory markers: High-sensitivity CRP (hs-CRP), the most responsive general marker Erythrocyte sedimentation rate (ESR) Fibrinogen Condition-specific markers: Rheumatoid arthritis: RF, anti-CCP, DAS28 score Hashimoto thyroiditis: TPO antibodies, thyroglobulin antibodies, TSH Psoriasis: PASI score, BSA involvement IBD: Fecal calprotectin, SES-CD or Mayo score Lupus: ANA, anti-dsDNA, complement C3/C4 Cytokine panels (when available): TNF-alpha IL-6 IL-1 beta IL-17 (particularly relevant for psoriasis and spondyloarthritis) The recommendation from most practitioners is baseline testing before starting, a 4 to 6 week interim check, and a full reassessment at 12 weeks

Aleix Cases declara haber recibido una beca, honorarios por consultora y ponencias de Vifor Pharma, honorarios por charlas y consultora de Astellas, Astra Zeneca, Bayer y Novo Nordisk